Tafinlar (dabrafenib)

pCPA File Number: 20786
Negotiation Status:
Concluded with an LOI
Indication(s):
Metastatic Melanoma
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0025-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: